These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15112303)

  • 1. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.
    Oh J; Henry RG; Pirzkall A; Lu Y; Li X; Catalaa I; Chang S; Dillon WP; Nelson SJ
    J Magn Reson Imaging; 2004 May; 19(5):546-54. PubMed ID: 15112303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.
    Laprie A; Catalaa I; Cassol E; McKnight TR; Berchery D; Marre D; Bachaud JM; Berry I; Moyal EC
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):773-81. PubMed ID: 18262090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
    Pirzkall A; Li X; Oh J; Chang S; Berger MS; Larson DA; Verhey LJ; Dillon WP; Nelson SJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):126-37. PubMed ID: 15093908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
    Zeng QS; Li CF; Liu H; Zhen JH; Feng DC
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):151-8. PubMed ID: 17289287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
    Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
    Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.
    Li X; Jin H; Lu Y; Oh J; Chang S; Nelson SJ
    NMR Biomed; 2004 Feb; 17(1):10-20. PubMed ID: 15011246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results.
    Di Costanzo A; Trojsi F; Giannatempo GM; Vuolo L; Popolizio T; Catapano D; Bonavita S; d'Angelo VA; Tedeschi G; Scarabino T
    J Exp Clin Cancer Res; 2006 Sep; 25(3):383-90. PubMed ID: 17167979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
    Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
    Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.
    Crawford FW; Khayal IS; McGue C; Saraswathy S; Pirzkall A; Cha S; Lamborn KR; Chang SM; Berger MS; Nelson SJ
    J Neurooncol; 2009 Feb; 91(3):337-51. PubMed ID: 19009235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.
    Saraswathy S; Crawford FW; Lamborn KR; Pirzkall A; Chang S; Cha S; Nelson SJ
    J Neurooncol; 2009 Jan; 91(1):69-81. PubMed ID: 18810326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.
    Laprie A; Pirzkall A; Haas-Kogan DA; Cha S; Banerjee A; Le TP; Lu Y; Nelson S; McKnight TR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):20-31. PubMed ID: 15850898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas.
    Catalaa I; Henry R; Dillon WP; Graves EE; McKnight TR; Lu Y; Vigneron DB; Nelson SJ
    NMR Biomed; 2006 Jun; 19(4):463-75. PubMed ID: 16763973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of gliomas by proton magnetic resonance spectroscopy.
    Oshiro S; Tsugu H; Komatsu F; Abe H; Onishi H; Ohmura T; Iwaasa M; Sakamoto S; Fukushima T
    Anticancer Res; 2007; 27(6A):3757-63. PubMed ID: 17970039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
    Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
    Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
    Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.
    Xu M; See SJ; Ng WH; Arul E; Back MF; Yeo TT; Lim CC
    Neurosurgery; 2005 May; 56(5):919-26; discussion 919-26. PubMed ID: 15854239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
    Law M; Oh S; Johnson G; Babb JS; Zagzag D; Golfinos J; Kelly PJ
    Neurosurgery; 2006 Jun; 58(6):1099-107; discussion 1099-107. PubMed ID: 16723889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.